Biotech Values

[dav1234]

Mylan (MYL) may be looking for acquisitions to build upon its product line and expand geographically, and is said to be considering deals valued at “well over” $4B. Key areas it's looking to bolster include specialty drugs and deals to widen its range of delivery, including firms that produce topically applied drugs, which would compliment its already strong core pill-related business. Some targets its considering globally include generic manufacturers in emerging markets, such as Jordanian drug maker Hikma Pharmaceuticals